Loading
Life sciences · Journal article
Biology Direct · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Tumor immune escape limits the effectiveness of current anticancer treatments, particularly immune checkpoint blockade. Tumor-intrinsic alterations and host immune dysfunction have been widely studied. Yet the role of persistent pathogen infections as an external evolutionary force shaping tumor immunity remains poorly understood. Recent evidence indicates that oncogenic and tumor-associated pathogens both initiate malignant transformation and persistently remodel the tumor immune microenvironment. This remodeling fosters immune tolerance, tumor progression, and therapy resistance. In this review, we propose a pathogen-driven immune remodeling framework. This framework systematically explains how viruses, bacteria, fungi, and parasites regulate tumor immune escape through interconnected mechanisms. These mechanisms include immune checkpoint activation, recruitment and polarization of immunosuppressive cells such as regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells, reprogramming of cytokine networks, metabolic adaptation, and disruption of antigen processing and presentation. Moreover, we highlight the dynamic interactions among pathogens, tumor cells, and the host immune system. These interactions create an infection-induced microenvironment marked by persistent inflammation and immune dysfunction. Importantly, we discuss how pathogen-mediated immune remodeling may contribute to resistance or attenuated responses to immunotherapy. We also explore new therapeutic strategies that target pathogen-related immune escape pathways, such as combination immunotherapy, microbial interventions, and personalized immunomodulation. This review integrates infectious factors into current tumor immunology models. It provides a conceptual framework for understanding tumor immune evolution and suggests new opportunities for precision immunotherapy in infection-associated and refractory cancers.